Cargando…

Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli

BACKGROUND AND AIM: Probiotics are beneficial microorganisms for humans and animals. In this study, we developed a microencapsulated probiotic with antibacterial activity against avian pathogenic Escherichia coli (APEC). MATERIALS AND METHODS: Alignment of the 16S rRNA sequences of the isolate WU222...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitsuwan, Watcharapong, Saengsawang, Phirabhat, Jeenkeawpieam, Juthatip, Nissapatorn, Veeranoot, Pereira, Maria de Lourdes, Kitpipit, Warangkana, Thomrongsuwannakij, Thotsapol, Poothong, Saranporn, Vimon, Sasi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Veterinary World 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420709/
https://www.ncbi.nlm.nih.gov/pubmed/37576777
http://dx.doi.org/10.14202/vetworld.2023.1131-1140
_version_ 1785088790199533568
author Mitsuwan, Watcharapong
Saengsawang, Phirabhat
Jeenkeawpieam, Juthatip
Nissapatorn, Veeranoot
Pereira, Maria de Lourdes
Kitpipit, Warangkana
Thomrongsuwannakij, Thotsapol
Poothong, Saranporn
Vimon, Sasi
author_facet Mitsuwan, Watcharapong
Saengsawang, Phirabhat
Jeenkeawpieam, Juthatip
Nissapatorn, Veeranoot
Pereira, Maria de Lourdes
Kitpipit, Warangkana
Thomrongsuwannakij, Thotsapol
Poothong, Saranporn
Vimon, Sasi
author_sort Mitsuwan, Watcharapong
collection PubMed
description BACKGROUND AND AIM: Probiotics are beneficial microorganisms for humans and animals. In this study, we developed a microencapsulated probiotic with antibacterial activity against avian pathogenic Escherichia coli (APEC). MATERIALS AND METHODS: Alignment of the 16S rRNA sequences of the isolate WU222001 with those deposited in GenBank revealed that the isolate was Pediococcus acidilactici with 99.6% homology. This bacterium was characterized as a probiotic based on its tolerance toward in vitro gastrointestinal tract (GIT) conditions, hydrophobicity, and auto-aggregation. The antibacterial activity of the probiotic’s culture supernatant against APEC was investigated using a broth microdilution assay. Pediococcus acidilactici was microencapsulated using sodium alginate and agar with diameters ranging from 47 to 61 μm. Then, physicochemical characteristics and stability of the microcapsules were determined. RESULTS: The isolate was characterized as a probiotic based on its resistance to low pH, bile salts, and pancreatin, with relative values of 79.2%, 70.95%, and 90.64%, respectively. Furthermore, the bacterium exhibited 79.56% auto-aggregation and 55.25% hydrophobicity at 24 h. The probiotic’s culture supernatant exhibited strong antibacterial activity against clinical APEC isolates with minimum inhibitory concentration and minimum bactericidal concentration of 12.5% and 25% v/v, respectively. Microencapsulation-enhanced bacterial viability in GIT compared to free cells. Moreover, 89.65% of the encapsulated cells were released into the simulated intestinal fluid within 4 h. The viable count in microcapsules was 63.19% after 3 months of storage at 4°C. CONCLUSION: The results indicated that the culture supernatant of P. acidilactici inhibited the growth of APEC. In addition, microencapsulation extends the viability of P. acidilactici under harsh conditions, indicating its potential application in the feed production.
format Online
Article
Text
id pubmed-10420709
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Veterinary World
record_format MEDLINE/PubMed
spelling pubmed-104207092023-08-12 Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli Mitsuwan, Watcharapong Saengsawang, Phirabhat Jeenkeawpieam, Juthatip Nissapatorn, Veeranoot Pereira, Maria de Lourdes Kitpipit, Warangkana Thomrongsuwannakij, Thotsapol Poothong, Saranporn Vimon, Sasi Vet World Research Article BACKGROUND AND AIM: Probiotics are beneficial microorganisms for humans and animals. In this study, we developed a microencapsulated probiotic with antibacterial activity against avian pathogenic Escherichia coli (APEC). MATERIALS AND METHODS: Alignment of the 16S rRNA sequences of the isolate WU222001 with those deposited in GenBank revealed that the isolate was Pediococcus acidilactici with 99.6% homology. This bacterium was characterized as a probiotic based on its tolerance toward in vitro gastrointestinal tract (GIT) conditions, hydrophobicity, and auto-aggregation. The antibacterial activity of the probiotic’s culture supernatant against APEC was investigated using a broth microdilution assay. Pediococcus acidilactici was microencapsulated using sodium alginate and agar with diameters ranging from 47 to 61 μm. Then, physicochemical characteristics and stability of the microcapsules were determined. RESULTS: The isolate was characterized as a probiotic based on its resistance to low pH, bile salts, and pancreatin, with relative values of 79.2%, 70.95%, and 90.64%, respectively. Furthermore, the bacterium exhibited 79.56% auto-aggregation and 55.25% hydrophobicity at 24 h. The probiotic’s culture supernatant exhibited strong antibacterial activity against clinical APEC isolates with minimum inhibitory concentration and minimum bactericidal concentration of 12.5% and 25% v/v, respectively. Microencapsulation-enhanced bacterial viability in GIT compared to free cells. Moreover, 89.65% of the encapsulated cells were released into the simulated intestinal fluid within 4 h. The viable count in microcapsules was 63.19% after 3 months of storage at 4°C. CONCLUSION: The results indicated that the culture supernatant of P. acidilactici inhibited the growth of APEC. In addition, microencapsulation extends the viability of P. acidilactici under harsh conditions, indicating its potential application in the feed production. Veterinary World 2023-05 2023-05-30 /pmc/articles/PMC10420709/ /pubmed/37576777 http://dx.doi.org/10.14202/vetworld.2023.1131-1140 Text en Copyright: © Mitsuwan, et al. https://creativecommons.org/licenses/by/4.0/Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mitsuwan, Watcharapong
Saengsawang, Phirabhat
Jeenkeawpieam, Juthatip
Nissapatorn, Veeranoot
Pereira, Maria de Lourdes
Kitpipit, Warangkana
Thomrongsuwannakij, Thotsapol
Poothong, Saranporn
Vimon, Sasi
Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli
title Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli
title_full Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli
title_fullStr Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli
title_full_unstemmed Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli
title_short Development of a microencapsulated probiotic containing Pediococcus acidilactici WU222001 against avian pathogenic Escherichia coli
title_sort development of a microencapsulated probiotic containing pediococcus acidilactici wu222001 against avian pathogenic escherichia coli
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420709/
https://www.ncbi.nlm.nih.gov/pubmed/37576777
http://dx.doi.org/10.14202/vetworld.2023.1131-1140
work_keys_str_mv AT mitsuwanwatcharapong developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli
AT saengsawangphirabhat developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli
AT jeenkeawpieamjuthatip developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli
AT nissapatornveeranoot developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli
AT pereiramariadelourdes developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli
AT kitpipitwarangkana developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli
AT thomrongsuwannakijthotsapol developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli
AT poothongsaranporn developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli
AT vimonsasi developmentofamicroencapsulatedprobioticcontainingpediococcusacidilacticiwu222001againstavianpathogenicescherichiacoli